Abstract-In this study we evaluated the cardiac effects of a pharmaceutical formulation developed by including angiotensin (Ang)-(1-7) in hydroxypropyl ␤-cyclodextrin (HP␤CD), in normal, infarcted, and isoproterenol-treated rats. Myocardial infarction was produced by left coronary artery occlusion. Isoproterenol (2 mg/kg, IP) was administered daily for 7 days. Oral administration of HP␤CD/Ang-(1-7) started immediately before infarction or associated with the first dose of isoproterenol. After 7 days of treatment, the rats were euthanized, and the Langendorff technique was used to analyze cardiac function. In addition, heart function was chronically (15, 30, 50 days) analyzed by echocardiography. Cardiac sections were stained with hematoxylin/eosin and Masson trichrome to evaluate cardiac hypertrophy and damage, respectively. Pharmacokinetic studies showed that oral HP␤CD/Ang-(1-7) administration significantly increased Ang-(1-7) on plasma whereas with the free peptide it was without effect. Oral administration of HP␤CD/Ang-(1-7) (30 g/kg) significantly reduced the deleterious effects induced by myocardial infarction on systolic and diastolic tension, ϮdT/dt, perfusion pressure, and heart rate. Strikingly, a 50% reduction of the infarcted area was observed in HP␤CD/Ang-(1-7)-treated rats. Furthermore, HP␤CD/Ang-(1-7) attenuated the heart function impairment and cardiac remodeling induced by isoproterenol. In infarcted rats chronically treated with HP␤CD/Ang-(1-7), the reduction of ejection fraction and fractional shorting and the increase in systolic and diastolic left ventricular volumes observed in infarcted rats were attenuated. Altogether, these findings further confirm the cardioprotective effects of Ang-(1-7). More importantly, our data indicate that the HP␤CD/Ang-(1-7) is a feasible formulation for oral administration of Ang-(1-7), which can be used as a cardioprotective drug. (Hypertension. 2011;57:477-483.) • Online Data Supplement
A ngiotensin (Ang)-(1-7) is a biologically active peptide of the renin-angiotensin system, of which the actions are often opposite to those attributed to Ang II. This fact, in addition to the Ang-(1-7) ability to inhibit the angiotensinconverting enzyme (ACE) 1 and to the increase in its plasma levels after administration of drugs that block the renin-angiotensin system activity, 2 suggests that this peptide could represent a target to develop novel and innovative cardioprotective drugs. Indeed, several studies have demonstrated that this heptapeptide exerts important beneficial effects in the heart, such as amplification of the coronary dilation induced by bradykinin, 3, 4 reduction of release of norepinephrine, 5 improvement in cardiac function, 6 -9 and regulation of cardiac remodeling and cell growth. 10 -14 These effects are generally mediated by the activation of the G protein-coupled receptor Mas, 3, 8, 13, 15 which was identified as an endogenous binding site for Ang-(1-7). 16 Thus, Ang-(1-7), in conjunction with its receptor Mas and ACE2, the main enzyme involved in its formation, 17 represents a cardioprotective axis within the renin-angiotensin system, of which its actions balance the ACE-Ang II-Ang II type 1 receptor effects.
As a result of these findings, new therapeutic approaches targeting the ACE2-Ang-(1-7)-Mas axis have been proposed. 18, 19 For instance, it has been demonstrated that activation of endogenous ACE2 using a small molecule called XNT reverses the cardiac fibrosis observed in spontaneously hypertensive rats, leading to a significant improvement in heart function. 19 The first synthetic compound able to mimic the Ang-(1-7) effects was described by Wiemer et al 18 and Santos and Ferreira. 20 This compound, AVE 0991, improves the cardiac function of normal and infarcted hearts 6, 21 and protects the heart against the deleterious effects of the isoproterenol (ISO) treatment. 22 Recently, it has been suggested that the inclusion of Ang-(1-7) into the oligosaccharide hydroxypropyl ␤-cyclodextrin (HP␤CD) 23 cavity could protect the peptide during the passage through the gastrointestinal tract when orally administrated. Considering the potential for using Ang-(1-7) to treat cardiovascular diseases, the aim of this study was to evaluate the cardiac effects of the HP␤CD/ Ang-(1-7) inclusion compound in normal, infarcted, and ISO-treated rats.
Methods
The procedures used for isolated heart perfusion, echocardiography analysis, evaluation of cardiac hypertrophy, and the area of damage induced by ISO and infarction are described in the online Data Supplement (please see at http://hyper.ahajournals.org).
Animals
Male Wistar rats weighing 210 to 280 g were used in this study. The animals were provided by the animal facilities of the Biological Sciences Institute (Centro de Bioterismo, Federal University of Minas Gerais) and housed in a temperature-and humidity-controlled room maintained on a 12:12-hour light-dark schedule with free access to food and water. All of the animal procedures were performed in accordance with institutional guidelines approved by local authorities.
Effect of HP␤CD/Ang-(1-7) Administration on Plasma Ang-(1-7) Levels
We conducted tests with Wistar rats to estimate the bioavailability of oral administration of aqueous formulations of free Ang-(1-7) peptide with that of the inclusion compound of Ang-(1-7) with HP␤CD. The animals were euthanized and blood samples were collected before and with 2, 6, and 24 hours of vehicle (distilled water) or drug administration. Plasma Ang-(1-7) levels were evaluated using an established radioimmunoassay, according to Botelho et al. 24 
Animal Models of Cardiac Dysfunction
The animals were submitted to 2 different maneuvers for induction of cardiac dysfunction, myocardial infarction (MI) and treatment with ISO. MI was induced by proximal left anterior descending coronary artery occlusion. In our hands, this procedure produced a started on the first day of MI or ISO treatment, and the experimental procedures were performed at the end of the 7-day treatment period (isolated heart preparation) or for Յ50 days after the beginning of the treatment (echocardiography groups). The final volumes of gavage (HP␤CD and HP␤CD/Ang- [1] [2] [3] [4] [5] [6] [7] ) and intraperitoneal injection (saline and ISO) were Ϸ0.5 mL and 0.2 mL, respectively.
Myocardial Infarction
MI was performed under anesthesia with 10% ketamine-2% xylazine (4:3, 0.1 mL/100 g, IP). The animals were placed in supine position on a surgical table, tracheotomized, intubated, and ventilated with room air using a respirator for small rodents. Subdermal electrodes were placed to allow the determination of ECG (Cardiofax, Nihon Kohden). The chest was opened by a left thoracotomy at the third or fourth intercostal space. After incision of the pericardium, the heart was quickly removed from the thoracic cavity and moved to the left to allow access to the proximal left anterior descending coronary artery. A 4-0 silk suture was snared around the left anterior descending and carefully ligated to occlude the vessel. The heart was then placed back, and the chest was closed with 4-0 silk sutures. Sham-operated rats were treated in the same manner, but the coronary artery was not ligated. After surgical procedures, ECG tracings were obtained to confirm the myocardial ischemia through ST-segment elevation and an increase in R-wave amplitude.
ISO Treatment
Heart dysfunction was induced by administration of ISO (2 mg/kg per day, IP) diluted in saline for 7 days. 22, 25 This dose of ISO was chosen because, after 7 days of treatment, it induces significant changes in cardiac histology followed by deleterious effects in heart function with low mortality rates. 25 To test whether the HP␤CD altered the blood pressure in normotensive control rats or in the ISO-treated rats, additional conscious animals (nϭ5 per group) had their mean arterial pressure measured indirectly by tail-cuff method (RTBP 2000 Kent-Scientific USA) before and after the treatment. Windaq Acquisition 1.58 and Windaq Analysis 2.29 software (DATAQ Instruments DI200AC) were used to record and analyze the data, respectively.
Statistical Analysis
All of the data are expressed as meanϮSEM. The cardiac function values of each animal were obtained through the average of 7 values (each value collected at 5-minute intervals during the 30-minute experimental period). The lesion area and total area of each animal were obtained by the average of all of the values acquired in each tissue section. Statistical significance was estimated using 1-way ANOVA followed by Newman-Keuls posttest. Student t test was used for the quantification of lesion area induced by ISO. In additional groups chronically treated, the echocardiography data were estimated using 2-way ANOVA followed by the Bonferroni posttest. The level of significance was set at PϽ0.05 (GraphPad Prism 4.0).
Results

Effect of HP␤CD/Ang-(1-7) Administration on Plasma Ang-(1-7) Levels
As shown in Figure 1 , oral administration of HP␤CD/Ang-(1-7) dramatically increased plasma Ang-(1-7) levels. The bioavailability of Ang-(1-7) delivered by HP␤CD/Ang-(1-7) was dramatically increased shortly after administration and continued to increase for Ն6 hours after administration ( Figure 1 ).
MI Model
No significant differences were observed in body weight and in heart and lung weights, normalized or not by the body weight, among all of the groups analyzed (please see Table S1 of the online Data Supplement at http://hyper.ahajournals.org). The absence of changes in the lung mass index indicated that, in our protocol, MI rats did not develop congestive heart failure. ECG tracings obtained after the surgical procedures showed an elevation in the ST segment in all of the infarcted animals, demonstrating the success of the technique used to promote MI (data not shown).
As expected, MI caused a significant decrease in the systolic and diastolic tensions, ϮdT/dt, and heart rate (HR) and induced an increase in perfusion pressure (PP). Treatment with HP␤CD/Ang-(1-7) produced a significant improvement in all of these cardiac functional parameters in infarcted animals. Systolic tension increased 33.9% (5.33Ϯ0.08 versus 3.98Ϯ0.14 g in vehicle-treated rats; Figure 2A ), diastolic tension 26.6% (1.00Ϯ0.01 versus 0.79Ϯ0.03 g in vehicletreated rats; Figure 2B ), ϩdT/dt 26% (91.49Ϯ1.78 versus 72.58Ϯ1.87 g/s in vehicle-treated rats; Figure 2C ), ϪdT/dt 27.5% (89.16Ϯ1.68 versus 69.95Ϯ2.53 g/s in vehicle-treated rats; Figure 2D ), and HR 9.9% (239.2Ϯ3.2 versus 217.6Ϯ0.7 bpm in vehicle-treated rats; Figure 2F ). In addition, HP␤CD/ Ang-(1-7) completely blocked the increase in PP induced by MI (61.71Ϯ1.67 versus 76.27Ϯ3.55 mm Hg in vehicletreated rats; Figure 2E ).
An injured area was observed in all of the hearts of animals submitted to the MI procedure ( Figure 3A) . Strikingly, the infarcted area was significantly lower in animals treated with HP␤CD/Ang-(1-7) when compared with vehicle-treated rats ( Figure 3A) . The infarcted area quantification revealed that the HP␤CD/Ang-(1-7) treatment significantly reduced the cardiac damage induced by ligation of the left coronary artery in Ϸ50% ( Figure 3B) .
Echocardiography analysis at 7 days after MI essentially showed the same profile observed in isolated hearts experiments, that is, an improvement in the cardiac function of rats administrated with HP␤CD/ Ang-(1-7) . Specifically, HP␤CD/ Ang-(1-7) increased ejection fraction and fractional shorting and decreased the systolic left ventricular (LV) volume of infarcted rats (please see Figures S1 and S2) . No significant changes in stroke volume, cardiac output, and HR were observed among all of the groups (please see Figure S3 ). Furthermore, in infarcted animals chronically treated with HP␤CD/Ang-(1-7) (50 days), the reduction of the ejection fraction and fractional shorting and the increase in the systolic and diastolic LV volumes observed in infarcted rats were significantly attenuated (please see Figures S1 and S2) . Again, no significant changes were observed in the stroke volume, cardiac output, and HR among all of the groups (please see Figure S3 ). Of note, the progressive decrease in the ejection fraction and in the fractional shorting observed in infarcted rats was not because of changes in HR, which remained essentially constant. Thus, the progressive increase in diastolic LV volume was the main mechanism underlying the maintenance of the stroke volume in the presence of a prominent decrease in the fractional shorting. Figure 4F ). However, the decrease in ϩdT/dt caused by ISO administration was unaffected by HP␤CD/Ang-(1-7) treatment ( Figure 4C ). No significant changes were observed in diastolic tension ( Figure  4B ). Hearts from rats treated only with HP␤CD/Ang-(1-7) presented a slight decrease in HR. Administration of ISO caused an extensive area of necrosis in hearts ( Figure 5C ), which was significantly reduced by the cotreatment with HP␤CD/Ang-(1-7) ( Figure 5D ). As observed in Figure 5E , quantification of this effect showed a reduction of Ϸ40% in the extension of the cardiac damage in the animals treated with HP␤CD/Ang- (1-7) . Figure 5A and 5B show heart sections from control and from an animal treated with HP␤CD/Ang-(1-7) alone, respectively.
ISO Model
As shown in Table S2 , ISO treatment induced a significant cardiac hypertrophy evidenced by the ratio between the heart weight and body weight. This effect was mainly attributed to the hypertrophy of the left ventricle because no significant differences in right ventricle/body weight and atria/body weight ratios were observed. The ISO hypertrophic effect was confirmed by the measurement of the diameter of cardiomyocytes from free wall LV and interventricular septum (Figure 6) . Administration of HP␤CD/Ang-(1-7) reduced the ISO effects on the cardiomyocyte diameters by Ϸ5.0% and 3.2% in free wall LV ( Figure 6B ) and interventricular septum (Figure 6C ), respectively. However, the antihypertrophic effect of the HP␤CD/Ang-(1-7) was not observed in the muscle mass index, probably because of the lower sensitivity of this method when compared with cardiomyocyte morphometry. Surprisingly, administration of HP␤CD/Ang-(1-7) alone reduced the diameter of cardiomyocytes from the interventricular septum. This effect was also observed in the LV mass index, although the diameter of the cardiomyocytes of the LV wall was not altered by the treatment.
Discussion
The most important finding of the current study is that once-a-day oral administration of the inclusion compound HP␤CD/Ang-(1-7) produced cardioprotective effects in 2 models of cardiac dysfunction, that is, MI and heart failure induced by ISO. This observation is in keeping with the cardioprotective role of Ang-(1-7)/Mas 2,16 and indicated that, as suggested before, the inclusion of Ang-(1-7) in HP␤CD is an effective way to orally administer this peptide. 23 It has been demonstrated that Ang-(1-7) is an important peptide involved in the regulation of blood pressure, 26, 27 cardiac function, 6,9,21,22 cardiac remodeling, 10, 11 and cell growth, 12, 13, 27, 28 suggesting a potential therapeutic use of Ang-(1-7) in several disease conditions, such as cardiac hypertrophy, heart failure, hypertension, preeclampsia, and cancer. However, similar to other peptides, Ang-(1-7) could experience degradation in the gastrointestinal tract. 20 Indeed, our data with administration of the free peptide support this concept. To circumvent this limitation, the recent inclusion of Ang-(1-7) in HP␤CD 23 allowed us to administer Ang-(1-7) orally and test its effects in rat hearts. We have observed a substantial increase in plasma Ang-(1-7) concentration 6 hours after oral administration of the inclusion compound as compared with the minor changes observed after administration of the free form of the peptide. This is in keeping with the concept that cyclodextrins can protect substances for delivery at the distal parts of the gastrointestinal tract. 29 The colon is a superior organ for peptide absorption after oral ingestion, and many studies indicate that colon-specific drug carriers may be used for delivering peptide drugs to that organ. 29 For colon-specific drug delivery, a variety of compounds, including polysaccharides, has been used. They are chemically stable, safe, nontoxic, hydrophilic, and biodegradable and, hence, excellent candidates for drug delivery systems. A large number of polysaccharides, such as cyclodextrins, has been tried for their potential as colon-specific drug carrier systems. 29 Here we demonstrated the feasibility of the use of HP␤CD as a nanocarrier for Ang-(1-7) delivery.
Once-a-day HP␤CD/Ang-(1-7) administration improved all of the functional cardiac parameters in the infarcted hearts. These findings are in accordance with previous data showing that Ang-(1-7) infusion 9 tide mimic AVE 0991 21 protected the heart against injuries induced by MI. For example, as observed in studies using AVE 0991, 21 HP␤CD/Ang-(1-7) administration was able to completely inhibit the vasoconstriction viewed in infarcted hearts. Even with 50 days of treatment with the inclusion compound, no evidence for toxic effects was observed. In addition, the beneficial effects of the HP␤CD/Ang-(1-7) formulation were evident with long-term administration.
Cardiomyocyte diameter analysis revealed that HP␤CD/ Ang-(1-7) treatment reduced the hypertrophic effect induced by ISO. A similar finding was observed in transgenic animals whose plasma Ang-(1-7) levels are 2.5-fold higher 25 and in AVE 0991-treated rats. 22 Furthermore, the treatment with the inclusion compound reduced the damaged area caused by ISO administration and, consequently, preserved the cardiac function. Many studies have shown that Ang-(1-7) possesses antitrophic and antifibrotic effects in cardiac cells. 10 -13,22,25 For instance, Grobe et al 10, 11 found that chronic infusion of Ang-(1-7) attenuates the cardiac remodeling in Ang IItreated rats 11 and in deoxycorticosterone acetate-salt rats. 10 Of note, the antihypertrophic effect of the HP␤CD/Ang-(1-7) was not observed in the muscle mass index, likely because of the lower sensitivity of this method when compared with cardiomyocyte morphometry.
In accordance with our previous study, 22 ISO administration did not alter the blood pressure with 7 days of treatment, confirming that the cardiac hypertrophy observed in this model is caused by a blood pressure-independent mechanism. In addition, systemic blood pressure was not changed by HP␤CD/Ang-(1-7) administration. This observation corroborates previous studies showing that the Ang-(1-7) effects on blood pressure of normotensive animals are not prominent. 6, 10, 11, 30 In control hearts, HP␤CD/Ang-(1-7) alone induced only a slight decrease in HR. This could be interpreted as an unanticipated finding, because we and other have demonstrated that Ang-(1-7) and its analog AVE 0991 elicit an improvement on cardiac function of normal rats, including changes in contractility and perfusion. 3, 9, 22, 25 However, the possibility that the peptide, which in contrast with AVE 0991 is highly hydrosoluble, was washed out during the perfusion, probably accounts for this observation. These apparent discrepant results can also be explained, at least partially, by the final concentration of Ang-(1-7) that was achieved in the heart. Although plasma Ang-(1-7) concentration is 3-fold higher 2 hours after administration of the HP␤CD/Ang-(1-7), we do not exactly know its biodistribution. Thus, future studies addressing the pharmacokinetics of this compound are essential. Unexpectedly, HP␤CD/Ang-(1-7) treatment alone caused a decrease in cardiomyocyte diameters in the interventricular septum region. This finding suggests that activation of region specific antigrowth pathways could be an additional mechanism by which Ang-(1-7) induces its antihypertrophic actions.
In this study we have obtained evidence, using 2 different models, that administration of an orally active formulation of Ang-(1-7), the inclusion compound HP␤CD/Ang-(1-7), produced cardioprotective effects in rats. Considering that HP␤CD is essentially excreted in the feces and that the active substance entering the circulation with the use of this inclusion compound is the endogenous peptide Ang-(1-7), this may represent an important advantage of its use in comparison with synthetic derivatives. The possibility of using an orally active formulation of Ang-(1-7) opens new perspectives for the study and treatment of cardiovascular diseases.
Perspectives
The compound HP␤CD/Ang-(1-7) produced beneficial effects in rat hearts, such as improvement of cardiac function (especially at 7 days of treatment), reduction of the damaged area caused by MI and ISO treatment, and reduction of the cardiac hypertrophy induced by ISO. Thus, our current findings confirm and extend previous data demonstrating the beneficial effects of this peptide in hearts and, more importantly, indicate that this inclusion compound is a feasible formulation for oral administration of Ang-(1-7). Altogether, these results suggest that HP␤CD/Ang-(1-7) could be considered as a putative new and innovative therapeutic drug for treatment of cardiovascular diseases.
Sources of Funding
This work was partially supported by Coordenação de Aperfeiçoa-mento de Pessoal de Nível Superior, Conselho Nacional de Desenvolvimento Científico e Tecnológico, and Fundação de Amparo à Pesquisa de Minas Gerais.
